Clinical trials: Myeloid
Isocitrate Dehydrogenase Gene Mutation
A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH
An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in subjects with advanced relapsed, refractory, or resistant hematological malignancies that harbor IDH…
- Trial name
- NCT04764474
- Testing
- HMPL-306
- Where
- 15 sites in United States, Spain
- Volunteers
- 46 people
- Sponsor
- Hutchmed
Chronic Phase Chronic Myeloid Leukemia
Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
This study proposes to evaluate the number of chronic, Grade 1 or 2, non-hematologic Adverse Events (AEs) that reduce in grade or resolve at 3 months after switching therapy from imatinib to dasatinib.
- Trial name
- NCT01660906
- Testing
- Dasatinib
- Where
- 22 sites in United States, France and 3 more
- Volunteers
- 39 people
- Sponsor
- Bristol-Myers Squibb
Leukaemia, Myelocytic, Acute
A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML)
This study is a phase I, open-label study to determine recommended phase 2 dose (RP2D) and regimen for the orally administered lysine specific demethylase 1 (LSD1) inhibitor GSK2879552, alone or in combination with All-Trans…
- Trial name
- NCT02177812
- Testing
- GSK2879552, ATRA
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 41 people
- Sponsor
- GlaxoSmithKline
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)
This study evaluates the safety and tolerability of escalating doses of BP1002 (Liposomal Bcl-2 Antisense Oligodeoxynucleotide) in patients with refractory/relapsed AML.
- Trial name
- NCT05190471
- Testing
- BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide, Decitabine (in combination with BP1002)
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Bio-Path Holdings, Inc.
Nucleophosmin 1-mutated Acute Myeloid Leukemia
Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML
The primary objective of this study is to evaluate the efficacy of entospletinib (ENTO) compared to placebo when added to chemotherapy in previously untreated nucleophosmin-1 mutated (NPM1-m) acute myeloid leukemia (AML), as…
- Trial name
- NCT05020665
- Testing
- Entospletinib, Cytarabine, Anthracycline
- Where
- 83 sites in United States, Brazil and 10 more
- Volunteers
- 15 people
- Sponsor
- Kronos Bio
Acute Myelogenous Leukemia
Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML)
The goal of this study is to find the safest dose of Pixantrone (BBR 2778) that can be given to patients with Acute Myelogenous Leukemia (AML). After the safest dose is found, up to an additional 86 patients will be enrolled.
- Trial name
- NCT00106600
- Testing
- Pixantrone IV infusion
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- CTI BioPharma
Leukemia
Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias
RATIONALE: Drugs used in chemotherapy, such as temozolomide and VNP40101M, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00098436
- Testing
- laromustine, temozolomide
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Vion Pharmaceuticals
Acute Myeloid Leukemia
Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Tamibarotene is being studied as a treatment for participants with a type of leukemia called acute myeloid leukemia, or AML for short.
- Trial name
- NCT04905407
- Testing
- Tamibarotene, Venetoclax, Azacitidine
- Where
- 28 sites in United States, France
- Volunteers
- 66 people
- Sponsor
- Syros Pharmaceuticals
CML (Chronic Myelogenous Leukemia), Chronic Phase CML
ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants
The purpose of this study is to evaluate the safety, tolerability and determine the recommended dose for further clinical evaluation of ELVN-001 in Japanese patients with chronic phase chronic myeloid leukemia with and without…
- Trial name
- CML (NCT06787144)
- Testing
- ELVN-001
- Where
- 4 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Enliven Therapeutics
Chronic Myelogenous Leukemia
Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)
The study will assess the role of high-dose imatinib mesylate, in patients who have taken imatinib mesylate for at least 1 year at the standard dose, in achieving a major molecular response (a measure of the level of chronic…
- Trial name
- NCT00171899
- Testing
- imatinib mesylate
- Where
- Canada
- Volunteers
- 80 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
CC-90009-AML-001 is a phase 1, open-label, dose escalation and expansion, study in subjects with relapsed or refractory acute myeloid leukemia and relapsed or refractory higher-risk myelodysplastic syndrome.
- Trial name
- NCT02848001
- Testing
- CC-90009
- Where
- 20 sites in United States, Canada and 4 more
- Volunteers
- 101 people
- Sponsor
- Celgene
Healthy Volunteers
Safety and Tolerability of ZE74-0282 in Healthy Volunteers
This first-in-human, randomized, double-blind, placebo-controlled Phase 1 study evaluates the safety, tolerability, and pharmacokinetics of single, split, and multiple oral doses of ZE74-0282 under fasted or fed conditions in…
- Trial name
- NCT07527221
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Eilean Therapeutics AU Pty Ltd
Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL)
Study of the Glutaminase Inhibitor CB-839 in Leukemia
Many tumor cells, in contrast to normal cells, have been shown to require the amino acid glutamine to produce energy for growth and survival.
- Trial name
- NCT02071927
- Testing
- CB-839, CB-Aza
- Where
- 5 sites in United States
- Volunteers
- 43 people
- Sponsor
- Calithera Biosciences, Inc
Anemia, Non-Myeloid Malignancies
Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin Alfa
The purpose of this study is to develop a functional capacity screening tool (FCST) that estimates at baseline the functional capacity of anemic subjects with nonmyeloid malignancies receiving multicycle chemotherapy.
- Trial name
- NCT00540696
- Testing
- darbepoetin alfa
- Volunteers
- 300 people
- Sponsor
- Amgen
Myeloid Tumor
A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Myeloid Tumor
This is a phase I study evaluating the safety, tolerability and preliminary efficacy of IBI322 in Myeloid tumor patients.
- Trial name
- NCT05148442
- Testing
- IBI322
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Advanced MDS, AML
Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML
This is an open-label Phase 1b study of NEROFE following a traditional 3+3 design to assess safety and to determine the Recommended Phase 2 Dose (RP2D) of NEROFE in patients with MDS or AML.
- Trial name
- NCT04365179
- Testing
- Nerofe
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Immune System Key Ltd
Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
CLN-049-001 is a Phase 1/2, open-label, multicenter, first-in-human trial of CLN-049 in patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- Conditions
- Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), TP53-mutated MDS and AML
- Trial name
- NCT05143996
- Testing
- CLN-049
- Where
- 17 sites in United States
- Volunteers
- 275 people
- Sponsor
- Cullinan Therapeutics Inc.
Myeloid Leukemia, Philadelphia Positive
Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
The aim of this study is to support development of asciminib in the pediatric population (1 to <18 years) previously treated with one or more TKIs.
- Trial name
- NCT04925479
- Testing
- Asciminib Pediatric formulation group, Asciminib Adult formulation group
- Where
- 39 sites in United States, China and 12 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Lymphoma, Non-Hodgkin, Relapsed Non-Hodgkin Lymphoma
Long-Term Follow-up Study
This is an observational, non-interventional, LTFS of investigational Caribou therapies in patients who have participated in a parent study: a prior Caribou-sponsored clinical study, special access program, or an IIT.
- Conditions
- Lymphoma, Non-Hodgkin, Relapsed Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma
- Trial name
- LTFS (NCT05332054)
- Testing
- Caribou-sponsored investigational therapy
- Where
- 31 sites in United States
- Volunteers
- 150 people
- Sponsor
- Caribou Biosciences, Inc.
Related Donors Donating PBSC to a Family Member, Healthy Donors
MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies
This research study tests a new medicine for mobilizing stem cells so they can be collected and used for allogeneic stem cell transplant for treatment of hematological malignancies.
- Conditions
- Related Donors Donating PBSC to a Family Member, Healthy Donors, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia
- Trial name
- NCT04762875
- Testing
- MGTA-145, Plerixafor
- Where
- 8 sites in United States
- Volunteers
- 7 people
- Sponsor
- Ensoma
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.